Su-Ho Lim1, Jong Hoon Shin2, Ji-Woong Lee3, Young Lee4, Je Hyun Seo5. 1. Department of Ophthalmology, Daegu Veterans Health Service Medical Center, 42835, 60 Wolgok-ro, Dalseo-gu, Daegu, Republic of Korea. 2. Department of Ophthalmology, Pusan National University Yangsan Hospital, 50612, 20 Geumo-ro, Mulgeum-eup, Yangsan, Republic of Korea. 3. Department of Ophthalmology, Pusan National University Hospital, 49241, 179 Gudeok-ro, Seo-gu, Busan, Republic of Korea. 4. Veterans Medical Research Institute, Veterans Health Service Medical Center , 05368, Jinhwangdo-ro 61-gil 53, Gangdong-gu, Seoul, Republic of Korea. 5. Veterans Medical Research Institute, Veterans Health Service Medical Center , 05368, Jinhwangdo-ro 61-gil 53, Gangdong-gu, Seoul, Republic of Korea. jazmin2@naver.com.
Abstract
PURPOSE: To investigate the differences in the eyelid and buccal microbiomes between patients receiving long-term prostaglandin analogs for open-angle glaucoma (PG-OAG) and naïve-OAG patients by using metagenomics. METHODS: Eyelid and buccal samples were collected from 30 PG-OAG and 32 naïve-OAG patients. The taxonomic composition of the microbiome was obtained via 16S rRNA gene sequencing, operational taxonomic unit analysis, and diversity analysis. Differential gene expression analysis (DEG) and Bland-Altman (MA) plots were used to determine taxon differences between the microbiomes of PG-OAG and naïve-OAG patients. RESULTS: The eyelid microbiome showed marginally significant differences, while the alpha-diversity of the buccal microbiome showed significant differences between PG-OAG and naïve-OAG patients. However, the beta-diversity of both eyelid and buccal microbiomes was higher in PG-OAG patients than in naïve-OAG patients. The MA plot showed cluster differences in the eyelid microbiome. DEG analysis of the eyelid microbiome revealed various taxa differences, including enrichment of Azomonas, Pseudomonas, and Granulicatella in PG-OAG patients over naïve-OAG patients, as well as significant depletion of Delftia and Rothia. In the buccal microbiome in PG-OAG patients, taxa such as Rikenella and Stenotrophomonas were significantly enriched. CONCLUSION: Our findings suggest that the eyelid microbiome differs between PG-OAG and naïve-OAG patients, raising concerns regarding the eyelid environment in patients receiving these drugs. The overexpressed microbiome in the eyelid area suggests that microbiota may change after the administration of glaucoma medications in OAG.
PURPOSE: To investigate the differences in the eyelid and buccal microbiomes between patients receiving long-term prostaglandin analogs for open-angle glaucoma (PG-OAG) and naïve-OAG patients by using metagenomics. METHODS: Eyelid and buccal samples were collected from 30 PG-OAG and 32 naïve-OAG patients. The taxonomic composition of the microbiome was obtained via 16S rRNA gene sequencing, operational taxonomic unit analysis, and diversity analysis. Differential gene expression analysis (DEG) and Bland-Altman (MA) plots were used to determine taxon differences between the microbiomes of PG-OAG and naïve-OAG patients. RESULTS: The eyelid microbiome showed marginally significant differences, while the alpha-diversity of the buccal microbiome showed significant differences between PG-OAG and naïve-OAG patients. However, the beta-diversity of both eyelid and buccal microbiomes was higher in PG-OAGpatients than in naïve-OAG patients. The MA plot showed cluster differences in the eyelid microbiome. DEG analysis of the eyelid microbiome revealed various taxa differences, including enrichment of Azomonas, Pseudomonas, and Granulicatella in PG-OAGpatients over naïve-OAG patients, as well as significant depletion of Delftia and Rothia. In the buccal microbiome in PG-OAGpatients, taxa such as Rikenella and Stenotrophomonas were significantly enriched. CONCLUSION: Our findings suggest that the eyelid microbiome differs between PG-OAG and naïve-OAG patients, raising concerns regarding the eyelid environment in patients receiving these drugs. The overexpressed microbiome in the eyelid area suggests that microbiota may change after the administration of glaucoma medications in OAG.
Authors: Joon Mo Kim; Seok Hwan Kim; Ki Ho Park; So Young Han; Hyoung Sub Shim Journal: Invest Ophthalmol Vis Sci Date: 2011-02-03 Impact factor: 4.799
Authors: Chih-Chiun J Chang; Karina Somohano; Christine Zemsky; Anne-Catrin Uhlemann; Jeffrey Liebmann; George A Cioffi; Lama A Al-Aswad; Susan V Lynch; Bryan J Winn Journal: Invest Ophthalmol Vis Sci Date: 2022-08-02 Impact factor: 4.925